Replimune Group Inc (REPL)
6.43
-0.29
(-4.32%)
USD |
NASDAQ |
May 17, 16:00
6.43
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Enterprise Value: 19.65M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 19.65M |
| May 16, 2024 | 36.85M |
| May 15, 2024 | 42.38M |
| May 14, 2024 | 36.24M |
| May 13, 2024 | 28.87M |
| May 10, 2024 | 17.81M |
| May 09, 2024 | 37.46M |
| May 08, 2024 | 34.39M |
| May 07, 2024 | 46.68M |
| May 06, 2024 | 54.66M |
| May 03, 2024 | 50.98M |
| May 02, 2024 | 27.02M |
| May 01, 2024 | 22.11M |
| April 30, 2024 | 14.13M |
| April 29, 2024 | 28.25M |
| April 26, 2024 | 18.43M |
| April 25, 2024 | 1.844M |
| April 24, 2024 | 12.90M |
| April 23, 2024 | 18.43M |
| April 22, 2024 | 18.43M |
| April 19, 2024 | 20.27M |
| April 18, 2024 | 52.20M |
| April 17, 2024 | 66.94M |
| April 16, 2024 | 63.26M |
| April 15, 2024 | 61.42M |
| Date | Value |
|---|---|
| April 12, 2024 | 62.64M |
| April 11, 2024 | 65.72M |
| April 10, 2024 | 51.59M |
| April 09, 2024 | 71.24M |
| April 08, 2024 | 61.42M |
| April 05, 2024 | 76.16M |
| April 04, 2024 | 74.93M |
| April 03, 2024 | 57.73M |
| April 02, 2024 | 62.03M |
| April 01, 2024 | 98.88M |
| March 28, 2024 | 79.62M |
| March 27, 2024 | 84.53M |
| March 26, 2024 | 50.16M |
| March 25, 2024 | 72.25M |
| March 22, 2024 | 81.46M |
| March 21, 2024 | 81.46M |
| March 20, 2024 | 75.94M |
| March 19, 2024 | 85.15M |
| March 18, 2024 | 86.37M |
| March 15, 2024 | 101.72M |
| March 14, 2024 | 120.75M |
| March 13, 2024 | 129.35M |
| March 12, 2024 | 112.16M |
| March 11, 2024 | 121.36M |
| March 08, 2024 | 132.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-68.95M
Minimum
Dec 05 2023
2.185B
Maximum
Dec 01 2020
638.29M
Average
548.95M
Median
May 14 2020
Enterprise Value Benchmarks
| Esperion Therapeutics Inc | 482.55M |
| Gossamer Bio Inc | 119.01M |
| NovaBay Pharmaceuticals Inc | 5.156M |
| Palatin Technologies Inc | 22.26M |
| iBio Inc | 16.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.08M |
| Total Expenses (Quarterly) | 58.09M |
| EPS Diluted (Quarterly) | -0.82 |
| Earnings Yield | -50.31% |